Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
13(92.9%)
N/A
1(7.1%)
14Total
Phase 2(13)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT04962009Completed

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Role: lead

NCT03496467Phase 2Completed

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

Role: lead

NCT04280653Not ApplicableCompleted

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

Role: lead

NCT02014142Phase 2Completed

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Role: lead

NCT01037036Phase 2Completed

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Role: lead

NCT01481051Phase 2Completed

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Role: lead

NCT01481077Phase 2Completed

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Role: lead

NCT01229982Phase 2Completed

A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Role: lead

NCT00967811Phase 2Completed

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Role: lead

NCT00845299Phase 2Completed

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Role: lead

NCT00821002Phase 2Completed

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

Role: lead

NCT00650702Phase 2Completed

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT00820300Phase 2Completed

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Role: lead

NCT01287338Phase 2Terminated

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Role: lead

NCT00855517Phase 2Withdrawn

A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Role: lead

All 15 trials loaded